CA Patent

CA2619828A1 — Methods to enhance chemotherapy

Assigned to Genzyme Corp · Expires 2007-02-22 · 19y expired

What this patent protects

Antagonists of the interaction of CXCR4 receptor with its ligand enhance the effectiveness of chemotherapeutic methods in subjects afflicted with myeloid or hematopoietic malignancies.

USPTO Abstract

Antagonists of the interaction of CXCR4 receptor with its ligand enhance the effectiveness of chemotherapeutic methods in subjects afflicted with myeloid or hematopoietic malignancies.

Drugs covered by this patent

Patent Metadata

Patent number
CA2619828A1
Jurisdiction
CA
Classification
—
Expires
2007-02-22
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.